Interview with Zheng Hong, Chairman, China Pharmaceutical Industry Association…
You have a very long history in the Chinese pharmaceutical industry, first in the joint venture company…
China Pharmaceutical Industry Association (CPIA)
Last updated: 13.02.2014
Address: No. 20, Zhichun Rd., Haidian District, Beijing,China
Tel: -82080673
Company description
China Pharmaceutical Industry Association (CPIA) was founded in September 1988 and it is a non-governmental, non-profit association, Its members are mainly from large and medium sized pharmaceutical corporations, pharmaceutical machinery and medicinal glass packaging companies, regional pharmaceutical industrial associations, pharmaceutical research institutions, designing institutes, universities, colleges and secondary schools of this sector etc. CPIA is a national level society registered in the Ministry of Civil Affairs. The State-owned Assets Supervision and Administration Commission of the State Council directly administer the association. CPIA is a member and also a standing council director’s unit of China Federation of Industrial Economics.
Now CPIA has 338 members, the industrial output value of which (added together) is nearly up to 80 percent of that of the whole China’s pharmaceutical industry. CPIA also has 15 professional working units: 2 branch associations, 13 working & coordinating committees and communication groups.
Products and services
Industry association
Interviews
Related
China / Sinopharm Looks to mRNA Vaccines; Hong Kong Biotech Investment Continues to Boom; Another Big Manufacturing Investment for Lonza
The latest news from Chinese pharma and biotech, including news that state-owned Sinopharm is now developing its…
China / PhIRDA’s Song Ruilin on Strengthening Drug Supervision Capacity & Promoting Pharma Innovation
Song Ruilin, chairman of the China Pharmaceutical Innovation and Research Development Association (PhIRDA), picks…
China / CDE’s Drug Evaluation Report 2020: Part 1
The following is an overview from Accestra Consulting* of Part 1 of China’s Center for Drug Evaluation (CDE)’s…
China / Fosun Sales up 20%; MNC Price Manoeuvres Lead to Growth; Bayer Sees ‘Golden Age’ Ahead
The latest news from Chinese pharma, including Fosun Pharma’s 2021 interim results; how AstraZeneca, Bayer, Eli…
China / Striving for First-In-Class Drug Innovation with New Patent Law
In a comprehensive new piece, European Patent Attorney André Bourgouin and Adjunct Professor at CEIBS Eric…
China / Hong Chow Leaves Roche for Big New Role at Merck
In a big career move on a personal level and a sign of China’s continuing significance to global pharma, Hong…
China / Sinopharm Tops Brand Value Rankings; Simcere Splashes $565M on Alzheimer’s Drug; Innovent-Ascentage Tie-Up A Sign of Biotech Deals to Come?
The latest news from the Chinese pharmaceutical industry, including recent deals between domestic pharma giant…
China / Fosun-Kite Yescarta Approval Signals Beginning of CAR-T Era
A historic approval for Fosun-Kite’s CAR-T therapy Yescarta in China looks set to pave the way for further…
China / First CAR-T Approval; AZ & Bayer Take VBP Hit; Lonza Boosts Manufacturing Capacity
The latest news from Chinese pharma, including a historic first approval for Fosun Kite’s CAR-T therapy Yescarta;…
China / New Country President for MSD Amid Changes at HQ & Access Challenges
MSD, which has had a presence in China since 1990, recently appointed Belgian national Anna van Acker to lead its…
China / A New Era of Reform Transforming Regulatory Professionals
Writing in the June edition of DIA’s Global Forum magazine, Harbour BioMed’s Fang Zhou, in conversation…
Hong Kong / HKEX’s Aim to Become World’s #1 Biotech Listing Hub & Challenges for New CEO
With three years having passed since the Hong Kong Stock Exchange (HKEX)’s decision to allow pre-revenue biotechs…
